Incretin Atlas › Trials › ENLIGHT Phase IIb (NCT06921486)
ENLIGHT Phase IIb (NCT06921486)
Efsubaglutide alfa (supaglutide) · obesity
Design
- Molecule(s)
- Efsubaglutide alfa (supaglutide)
- Population
- obesity
- Official title
- The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)
- Sponsor
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
- Phase
- 2
- Registry status
- active not recruiting · 2025-03 → 2026-08
- Participants
- 1003
- Duration
- 18 weeks
- Registry
- NCT06921486
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20 mg QW | obesity china | 18 | 200 | — | —−10.6 % estimand not specified | — | — | — | — | — | — | — | press release |
| 20 mg Q2W | obesity china | 18 | 200 | — | —−9.7 % estimand not specified | — | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (2)
- 20 mg QW · weight_unsp · press release
Efsubaglutide α significantly reduced the weight of participants, with reductions of 10.58% and 9.70% in the QW and Q2W groups, respectively.
- 20 mg Q2W · weight_unsp · press release
Efsubaglutide α significantly reduced the weight of participants, with reductions of 10.58% and 9.70% in the QW and Q2W groups, respectively.
Primary sources
- Innogen (Yinnuo). Innogen to present Phase IIb ENLIGHT study results for Efsubaglutide Alfa at ADA 2026 (BioSpace mirror of PR Newswire) [press release]. 2026-05-29. Available from: https://www.biospace.com/press-releases/innogen-to-present-phase-iib-enlight-study-results-for-efsubaglutide-alfa-at-the-2026-ada-scientific-sessions
- ClinicalTrials.gov NCT06921486
How to cite this page
Medical Adviser's Group. Incretin Atlas: ENLIGHT Phase IIb (NCT06921486). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/enlight-phase-iib/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.